Sign In
Buy CRNX
$33.09
+0.480 (+1.47%)
At Close: Jun 03, 2026
Crinetics Pharmaceuticals: Attractive Speculative Bet On Market Weakness
05:53am, Thursday, 02'nd Jan 2025
Crinetics Pharmaceuticals is currently overvalued but holds strong Wall Street support with a $75.07 average price target, indicating a 47.43% upside. The FDA accepted Crinetics' NDA for paltusotine,
Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:44pm, Tuesday, 10'th Dec 2024
SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on December 10, 2024, the Compensation Committee of the Board of Directors granted non-
Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly
08:00am, Monday, 09'th Dec 2024
FDA Assigns a Prescription Drug User Fee Act Target Action Date of September 25, 2025 FDA Assigns a Prescription Drug User Fee Act Target Action Date of September 25, 2025
Novel Nonpeptide Drug Conjugate Platform to be Debuted, Featuring Preclinical Profile of Lead Candidate CRN09682 Targeting SST2-Expressing Tumors, which is on Track for IND Submission Early 2025
Crinetics Pharmaceuticals, Inc. (CRNX) Q3 2024 Earnings Call Transcript
11:00pm, Tuesday, 12'th Nov 2024
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Gayathri Diwakar - Head-Investor Relations Scott Struthers - Founder a
Novel Nonpeptide Drug Conjugate Platform to be Debuted, Featuring Preclinical Profile of Lead Candidate CRN09682 Targeting SST2-Expressing Tumors, which is on Track for IND Submission Early 2025
Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
04:05pm, Tuesday, 12'th Nov 2024
Submission of New Drug Application for Paltusotine for the Treatment of Acromegaly Completed Upsized Public Offering of $575M of Common Stock Debut of First Drug Candidate from a Novel Nonpeptide Drug
Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 11'th Nov 2024
SAN DIEGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on November 10, 2024, the Compensation Committee of Crinetics' Board of Directors grant
Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:40pm, Thursday, 10'th Oct 2024
SAN DIEGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on October 10, 2024, the Compensation Committee of Crinetics' Board of Directors grante
Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
11:55pm, Tuesday, 08'th Oct 2024
SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of nove
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
04:01pm, Tuesday, 08'th Oct 2024
SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of nove
Did this congressman benefit from a stock buy just before FDA approval?
10:23am, Monday, 07'th Oct 2024
On October 3, Representative Josh Gottheimer of New Jersey's 5th district disclosed a September 25 investment in Crinetics Pharmaceuticals (NASDAQ: CRNX), a mid-cap stock that no U.S. politician had p
Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly
04:05pm, Thursday, 26'th Sep 2024
SAN DIEGO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FD
Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:40pm, Tuesday, 10'th Sep 2024
SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on September 10, 2024, the Compensation Committee of Crinetics' Board of Directors gra
Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences
04:05pm, Thursday, 29'th Aug 2024
SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of nove
